Introduction
============

Peri-procedural complications in patients undergoing percutaneous coronary intervention (PCI) may be predicted by clinical and angiographic factors, and are associated with a poor short-term and late prognosis.[@ehy562-B1] Pre-procedural inhibition of the platelet adenosine diphosphate (ADP) receptor with oral ADP receptor antagonists has not been shown to reduce peri-procedural major adverse cardiac events (MACE) in randomized trials.[@ehy562-B8] In contrast, in the double-blind Cangrelor vs. Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX randomized trial, immediate pre-treatment with the potent, rapid-acting intravenous ADP antagonist cangrelor reduced the 48-h incidence of MACE compared with a loading dose of clopidogrel across a broad cross-section of patients undergoing PCI.[@ehy562-B11] However, few studies have comprehensively examined the relationship between high-risk lesion characteristics and peri-procedural adverse events after PCI, and whether the efficacy of cangrelor during PCI varies according to coronary lesion complexity is unknown. To address these issues, we performed a large-scale, blinded angiographic core laboratory-based analysis examining the relationship between high-risk PCI target lesion features and clinical outcomes from the CHAMPION PHOENIX trial.

Methods
=======

CHAMPION PHOENIX
----------------

The design and principal results of the CHAMPION PHOENIX trial have been previously described.[@ehy562-B11]^,^[@ehy562-B12] In brief, 11 145 ADP receptor inhibitor-naïve patients with stable ischaemic heart disease (SIHD) or an acute coronary syndrome \[ACS; non-ST-segment elevation ACS (NSTEACS); unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI)\] undergoing PCI at 153 international sites were enrolled between September 2010 and October 2012. Major exclusion criteria included treatment with an ADP receptor antagonist or abciximab within 7 days, treatment with eptifibatide, tirofiban, or fibrinolytic therapy within 12 h, uncontrolled hypertension, and impaired haemostasis. Following angiographic confirmation of eligibility, patients were randomized in a double-blind, double-dummy, active-controlled 1:1 ratio to receive a 30 µg/kg bolus of cangrelor followed by a 4 µg/kg/min infusion or a loading dose of 600 mg or 300 mg of clopidogrel prior to or immediately after PCI. Randomization was stratified by clinical syndrome acuity, intended loading dose of clopidogrel (600 mg vs. 300 mg), and site. Study drug infusion (cangrelor or matching placebo) was continued for at least 2 h and up to 4 h post-procedure, after which patients received a loading dose of clopidogrel or matching placebo and were transitioned to maintenance clopidogrel therapy (75 mg po qd). All patients received daily aspirin (75--325 mg) and other guideline-directed medical therapies. Percutaneous coronary intervention was performed using standard techniques and anticoagulation. Glycoprotein IIb/IIIa inhibitors were allowed only as rescue therapy during PCI to treat thrombotic complications. The primary efficacy endpoint was the occurrence of MACE within 48 h after PCI, defined as the composite rate of death, myocardial infarction (MI), stent thrombosis, or ischaemia-driven revascularization, as adjudicated by an independent events committee blinded to randomization. The components of the MACE endpoint have been previously defined.[@ehy562-B11]^,^[@ehy562-B12] The primary efficacy analysis population was the modified intention-to-treat cohort, defined as all patients undergoing PCI in whom study drug was administered (*n* = 10 942). The primary safety endpoint was the 48-h rate of severe bleeding not related to coronary artery bypass grafting, according to the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) criteria, assessed in the cohort of randomized patients who received at least one dose of study drug (*n* = 11 056). Follow-up continued for 30 days in all patients. The trial was approved by the institutional review board or ethics committee at all participating hospitals, and all patients signed informed consent prior to study enrolment.

Angiographic core laboratory analysis
-------------------------------------

As part of the CHAMPION PHOENIX trial, quantitative and qualitative coronary angiographic analysis (QCA) of all baseline and procedural angiograms was performed at an independent core laboratory (Cardiovascular Research Foundation, New York, NY, USA), blinded to treatment assignment and clinical outcomes.[@ehy562-B13] The following nine target lesion characteristics were pre-specified prior to any data analysis as angiographic high-risk features (HRF): long lesions, left main lesions, bifurcation lesions, thrombotic lesions, tortuous lesions (moderate or severe), angulated lesions (moderate or severe), eccentric lesions, calcified lesions (moderate or severe), and multi-lesion treatment. High-risk features were defined according to the standard definitions of the angiographic core laboratory. Long lesions were defined as length \>20 mm by QCA. A qualifying bifurcation lesion had a side branch lesion diameter stenosis ≥50% with reference diameter \>1.5 mm within 3 mm of the main branch. Thrombus was defined as a discrete, mobile intraluminal filling defect, with defined borders with or without associated contrast staining, or a total occlusion with convex edges and staining. Tortuosity (proximal to the target lesion) was defined as moderate if one bend \>90° or two bends \>75°, and severe if two bends \>90° or three bends \>75°. Lesion angulation was defined as moderate if 45--90° and severe if \>90°. An eccentric lesion had only one of its luminal edges compromised by a diameter stenosis \>25%. Finally, calcification was defined as moderate if radiopaque densities were noted only during the cardiac cycle and typically involving only one side of the vascular wall, and severe if radiopaque densities were noted without cardiac motion prior to contrast injection and generally involving both sides of the arterial wall.

Statistical methods
-------------------

Outcomes were analysed according to the number of angiographic HRFs treated (0, 1, 2, or ≥3) in all patients and separately in those with SIHD and ACS. For patients with multiple lesions, the number of HRFs per lesion was summed. Categorical variables were compared by the χ^2^ test. Continuous variables are summarized as mean ± standard deviation (SD) and were compared using ANOVA. Logistic regression was performed to identify the independent predictors of the 48-h MACE primary endpoint. The following variables were entered into the model which in prior studies have been frequently associated with peri-procedural and 30-day adverse events: age, sex, weight, US vs. non-US site, diabetes, hypertension, hyperlipidaemia, current smoker, prior stroke or transient ischaemic attack, prior MI, prior PCI, prior coronary artery bypass graft surgery, history of heart failure, peripheral artery disease, presentation with SIHD vs. ACS, femoral vs. non-femoral access site, planned 300 mg vs. 600 mg clopidogrel loading dose, use of bivalirudin, use of any drug-eluting stent (DES), number of HRFs, and cangrelor vs. clopidogrel randomization. Interaction between the number of HRFs per patient and randomization treatment for the 48-h MACE endpoint was tested using the Breslow--Day method. A two-sided *P*-value \<0.05 was considered significant. All statistical analyses were performed with SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Patients and high-risk features
-------------------------------

QCA of 13 418 target lesions was performed in 10 854 of 10 942 (99.2%) randomized patients undergoing PCI in CHAMPION PHOENIX. The mean number of HRFs per patient was 1.8 ± 1.4 (range 0--6 per lesion and 0--11 per patient); 1817 (16.7%), 3442 (31.7%), 2901 (26.7%), and 2694 (24.8%) patients had 0, 1, 2, and ≥3 HRFs treated, respectively (*Figure [1](#ehy562-F1){ref-type="fig"}*). The most common high-risk lesion types were bifurcation lesions, calcified lesions, thrombotic lesions, and long lesions (*Figure [2](#ehy562-F2){ref-type="fig"}*).

![Histogram of the number of high-risk target lesion features treated per patient. The mean number of high-risk features per patient was 1.8 ± 1.4 \[median (25th percentile, 75th percentile) = 2 (1, 2); range 0--11 per patient\]. Note: Each treated lesion has no more than nine high-risk features. For patients with more than one treated lesion, the total number of high-risk features is summed for each lesion. Thus, an individual patient with multiple treated lesions may have \>9 high-risk features. HRF, high-risk feature.](ehy562f1){#ehy562-F1}

![Presence (proportion) of qualifying high-risk features in 10 854 patients and in 13 418 lesions. Note: Each lesion has no more than nine high-risk features. For patients with more than one treated lesion, the total number of high-risk features is summed for each lesion. Thus, an individual patient with multiple treated lesions may have \>9 high-risk features. Analysis by quantitative and qualitative coronary angiography performed at an independent blinded core laboratory. NA, not applicable.](ehy562f2){#ehy562-F2}

Baseline demographic and clinical characteristics, medications, and procedural performance according to the number of HRFs treated are shown in *Table [1](#ehy562-T1){ref-type="table"}*. Patients with greater treated lesion complexity were older, were more frequently male and hyperlipidaemic, were less likely to have prior cardiac procedures and be treated in the USA, more frequently presented with an ACS, and were less likely to be treated with a 600 mg loading dose of clopidogrel (or matching placebo) and bivalirudin anticoagulation. Drug-elunting stents use was more common, bailout glycoprotein IIb/IIIa inhibitor administration was required more frequently, and procedural duration was longer in procedures with greater HRFs. Randomization to cangrelor vs. clopidogrel was balanced across the HRF groups. Table 1Baseline features according to the number of treated high-risk lesion characteristics0 HRF (Group a) (*n* = 1817)1 HRF (Group b) (*n* = 3442)2 HRF (Group c) (*n* = 2901)≥3 HRF (Group d) (*n* = 2694)*P-*value[\*](#tblfn2){ref-type="table-fn"}Pairwise comparisons[\*\*](#tblfn3){ref-type="table-fn"}Age (years)63.9  ± 11.062.9  ± 11.164.2  ± 11.065.0  ± 10.7\<0.0001b \< a,c \< dMale1274 (70.1%)2431 (70.6%)2130 (73.4%)1990 (73.9%)0.0004a,b \< c,dWeight (kg)86.1  ± 18.285.6  ± 18.084.9  ± 17.685.1  ± 17.70.10c \< aTreated in USA585 (47.2%)1270 (36.9%)995 (34.3%)965 (35.8%)\<0.0001c,d \< b \< aMedical history Hypertension1462/1813 (80.6%)2773/3435 (80.7%)2257/2892 (78.0%)2147/2689 (79.8%)0.15c,d \< a,b Hyperlipidaemia1195/1649 (72.5%)2106/3046 (69.1%)1738/2555 (68.0%)1641/2406 (68.2%)0.005b,c,d \< a Diabetes mellitus532/1815 (29.3%)909/3439 (26.4%)788/2896 (27.2%)801/2689 (29.8%)0.28b \< c \< a,d Current smoker466/1773 (26.3%)988/3376 (29.3%)840/2822 (29.8%)721/2620 (27.5%)0.59a,d \< b,c Prior myocardial infarction397/1799 (22.1%)697/3421 (20.4%)578/2880 (20.1%)578/2685 (21.5%)0.84--- Prior PCI530/1813 (29.2%)794/3437 (23.1%)614/2896 (21.2%)652/2689 (24.2%)0.0007b,c,d \< a Prior CABG242/1815 (13.3%)338/3437 (9.8%)233/2898 (8.0%)262/2692 (9.7%)\<0.0001c \< b,d \< a Prior stroke or TIA84/1807 (4.6%)164/3430 (4.8%)138/2896 (4.8%)126/2687 (4.7%)0.99--- History of heart failure198/1809 (10.9%)361/3438 (10.5%)303/2893 (10.5%)273/2688 (10.2%)0.43--- Peripheral artery disease154/1788 (8.6%)243/3412 (7.1%)217/2880 (7.5%)217/2675 (8.1%)0.98---Presentation Stable ischaemic heart disease1220 (67.1%)1999 (58.1%)1590 (54.8%)1527 (56.7%)\<0.0001b,c,d \< a NSTEACS459 (25.3%)944 (27.4%)743 (25.6%)721 (26.8%)0.24--- STEMI138 (7.6%)499 (14.5%)568 (19.6%)446 (16.6%)\<0.0001a \< b,c \< dRandomization Cangrelor899 (49.5%)1726 (50.1%)1411 (48.6%)1390 (51.6%)0.29c \< d Clopidogrel918 (50.5%)1716 (49.9%)1490 (51.4%)1304 (48.4%)0.29d \< cClopidogrel loading dose 300 mg388 (21.4%)871 (25.3%)770 (26.5%)745 (27.7%)\<0.0001a \< b,c \< d 600 mg1429 (78.6%)2571 (74.7%)2131 (73.5%)1949 (72.3%)\<0.0001d \< b,c \< aMedications pre/during PCI Aspirin1691/1816 (93.1%)3248/3440 (94.4%)2745/2898 (94.7%)2541/2692 (94.4%)0.11--- Low molecular weight heparin252 (13.9%)455 (13.2%)376/2899 (13.0%)398 (14.8%)0.32--- Unfractionated heparin1338 (73.6%)2704/3441 (78.6%)2318 (79.9%)2107 (78.2%)0.001a \< b,d \< c Bivalirudin498/1816 (27.4%)769 (22.3%)623/2900 (21.5%)623 (23.1%)0.005b,c,d \< a Glycoprotein IIb/IIIa inhibitor16 (0.9%)90 (2.6%)125 (4.3%)149 (5.5%)\<0.0001a \< b \< c \< dAccess site Femoral1366 (75.2%)2515 (73.1%)2078 (71.6%)2027 (75.2%)0.006b,c \< a,d Radial448 (24.7%)921 (26.8%)816 (28.1%)660 (24.5%)0.006a,d \< b,c Brachial3 (0.2%)6 (0.2%)7 (0.2%)7 (0.3%)0.84---PCI device Drug-eluting stent967 (53.2%)1868 (54.3%)1602 (55.2%)1627 (60.4%)\<0.0001a, b, c \< d Bare metal stent749 (41.2%)1469 (42.7%)1213 (41.8%)1154 (42.8%)0.47--- Balloon angioplasty103 (5.7%)171 (5.0%)160 (5.5%)129 (4.8%)0.39--- PCI duration (min)15.5  ± 14.219.1  ± 16.123.4  ± 19.031.0  ± 23.6\<0.0001a \< b\<c \< d[^1][^2][^3]

Clinical outcomes according to anatomic lesion complexity and randomization
---------------------------------------------------------------------------

The primary 48-h MACE endpoint increased progressively with PCI target lesion complexity, from 2.5% with 0 HRFs to 7.5% with ≥3 HRFs (*P* \< 0.0001), driven by increases in MI, stent thrombosis and ischaemia-driven revascularization (*Table [2](#ehy562-T2){ref-type="table"}* and *Figure [3](#ehy562-F3){ref-type="fig"}*). A similar pattern was observed at 30 days. In the entire patient population, cangrelor reduced the 48-h rate of MACE by 21% \[4.7% vs. 5.9%, odds ratio (OR) (95% CI) 0.79 (0.67, 0.93), *P* = 0.006\] compared with clopidogrel. The reduction in 48-h MACE with cangrelor compared with clopidogrel was consistent regardless of PCI lesion complexity and presentation with SIHD or ACS (*Figure [4](#ehy562-F4){ref-type="fig"}*). Cangrelor individually reduced the 48-h rates of MI \[3.8% vs. 4.7%, OR (95% CI) 0.80 (0.67--0.97), *P* = 0.02\] and stent thrombosis \[1.1% vs. 1.6%, OR (95% CI) 0.67 (0.48--0.94), *P* = 0.02\]. The reductions in MI and stent thrombosis with cangrelor compared with clopidogrel were independent of the number of treated HRFs and clinical syndrome acuity (*Figure [5](#ehy562-F5){ref-type="fig"}*). In *post hoc* analyses, the results were consistent when analysed according to American College of Cardiology/American Heart Association (ACC/AHA) classification,[@ehy562-B14] baseline reference vessel diameter, number of implanted stents, and total stent length ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Tables S1--S8](#sup1){ref-type="supplementary-material"}*). Table 2Major adverse cardiovascular and bleeding events according to the number of treated high-risk lesion characteristics0 HRF1 HRF2 HRF≥3 HRF*P*-value48-h event rates MACE46/1816 (2.5%)141/3440 (4.1%)188/2901 (6.5%)202/2694 (7.5%)\<0.0001  Death6/1816 (0.3%)6/3440 (0.2%)15/2901 (0.5%)9/2694 (0.3%)0.13  Myocardial infarction37/1816 (2.0%)112/3440 (3.3%)151/2901 (5.2%)161/2694 (6.0%)\<0.0001  Ischaemia-driven revascularization2/1816 (0.1%)19/3440 (0.6%)27/2901 (0.9%)16/2694 (0.6%)0.005  Stent thrombosis4/1816 (0.2%)34/3440 (1.0%)37/2901 (1.3%)44/2694 (1.6%)\<0.0001 GUSTO moderate or severe bleeding7/1849 (0.4%)14/3482 (0.4%)11/2922 (0.4%)718/2712 (0.7%)0.33 TIMI major or moderate bleeding3/1849 (0.2%)6/3482 (0.2%)5/2922 (0.2%)7/2712 (0.3%)0.8430-day event rates MACE68/1815 (3.7%)174/3431 (5.1%)231/2894 (8.0%)228/2691 (8.5%)\<0.0001  Death17/1815 (0.9%)30/3431 (0.9%)38/2894 (1.3%)29/2691 (1.1%)0.36  Myocardial infarction43/1815 (2.4%)119/3431 (3.5%)166/2894 (5.7%)167/2691 (6.2%)\<0.0001  Ischaemia-driven revascularization15/1815 (0.8%)31/3431 (0.9%)45/2894 (1.6%)27/2691 (1.0%)0.04  Stent thrombosis12/1815 (0.7%)47/3431 (1.4%)59/2894 (2.0%)54/2691 (2.0%)0.0005[^4]

![Major adverse cardiovascular event rates at 48 h according to the number of high risk features. The 95% confidence intervals for each rate estimate appear in parentheses. HRF, high-risk features; MACE, major adverse cardiovascular events.](ehy562f3){#ehy562-F3}

![Major adverse cardiovascular events at 48 h following randomization to cangrelor vs. clopidogrel according to the number of treated high-risk target lesion features. (*A*) All patients. The *P*-value for the trend relating the number of treated high-risk lesion features to the 48-h rate of major adverse cardiovascular events was \<0.0001 for both the clopidogrel-treated and cangrelor-treated groups, and the reduction with cangrelor was consistent regardless of target lesion complexity. (*B*) Further stratified by clinical syndrome acuity at the time of presentation. The reduction in peri-procedural adverse events with cangrelor compared with clopidogrel was consistent regardless of target lesion complexity and clinical presentation. Limit lines for each rate estimate represent 95% confidence intervals. ACS, acute coronary syndrome; HRF, high-risk features; MACE, major adverse cardiovascular events; SIHD, stable ischaemic heart disease.](ehy562f4){#ehy562-F4}

![Myocardial infarction and stent thrombosis at 48 h following randomization to cangrelor vs. clopidogrel according to the number of treated high-risk target lesion features. (*A*) Myocardial infarction, all patients; (*B*) Myocardial infarction, further stratified by clinical syndrome acuity at the time of presentation. (*C*) Stent thrombosis, all patients; (*D*) stent thrombosis, further stratified by clinical syndrome acuity at the time of presentation. Limit lines for each rate estimate represent 95% confidence intervals. ACS, acute coronary syndrome; HRF, high-risk features; MACE, major adverse cardiovascular events; SIHD, stable ischaemic heart disease.](ehy562f5){#ehy562-F5}

There were no significant differences after treatment with cangrelor vs. clopidogrel in the entire safety population in the 48-h rates of GUSTO severe or moderate bleeding \[0.6% vs. 0.3% respectively, OR (95% CI) 1.63 (0.92--2.90), *P* = 0.09\] or Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding \[0.3% vs. 0.1% respectively, OR (95% CI) 1.75 (0.73--4.18), *P* = 0.20\], and bleeding complications were unrelated to the number of HRFs (*Table [2](#ehy562-T2){ref-type="table"}*).

By multivariable analysis, the number of high-risk PCI characteristics, presentation with SIHD vs. ACS, use of a 300 mg vs. a 600 mg clopidogrel loading dose, peripheral artery disease, and treatment with clopidogrel rather than cangrelor were independent predictors of 48-h MACE (*Table [3](#ehy562-T3){ref-type="table"}*). Table 3Independent predictors of the primary composite endpoint of major adverse cardiovascular events at 48 hVariableAdjusted OR (95% CI)*P*-valueNumber of HRFs per patient 0 (reference)------ 11.68 (1.20, 2.36)\<0.0001 22.78 (2.00, 3.87)\<0.0001 ≥33.23 (2.33, 4.48)\<0.0001Stratified clopidogrel loading dose (300 mg vs. 600 mg)1.47 (1.22, 1.78)\<0.0001Peripheral artery disease (yes vs. no)1.49 (1.13, 1.96)0.004Presentation (SIHD vs. ACS)1.84 (1.52, 2.22)\<0.0001Treatment (cangrelor vs. clopidogrel)0.78 (0.66, 0.92)0.004[^5]

Discussion
==========

The principal findings from the present study from the CHAMPION PHOENIX trial, to our knowledge the largest blinded angiographic core laboratory analysis to date examining the impact of target lesion characteristics on peri-procedural outcomes after PCI, are: (i) The 48-h rates of MI, stent thrombosis, ischaemia-driven revascularization, and composite MACE increased progressively with the number of target lesion HRFs; (ii) Compared with an oral clopidogrel loading dose at the time of PCI, the rapid-acting, potent intravenous ADP receptor antagonist cangrelor reduced the 48-h rate of MACE by 21%, an effect that was consistent regardless of PCI lesion complexity and presentation with SIHD or ACS; (iii) By multivariable analysis, the number of high-risk PCI lesion characteristics and treatment with cangrelor vs. clopidogrel were independent predictors of the primary 48-h MACE endpoint; and (iv) Peri-procedural major bleeding rates were not related to PCI anatomic complexity, and were not significantly increased by treatment with cangrelor compared with clopidogrel.

Despite the major prognostic implications of peri-procedural complications,[@ehy562-B1] few studies have broadly examined the relationship between the extent of PCI lesion anatomic complexity and peri-procedural MACE, and no prior large-scale studies have employed a blinded angiographic core laboratory analysis to eliminate the potential biases inherent in assigning such correlations. In the present large-scale, international study in which there were few patient and lesion-specific exclusion criteria, DES use was more common, bailout glycoprotein IIb/IIIa inhibitor administration was required more frequently, and procedural duration was longer with PCI treatment of lesions with greater HRFs. Anatomic PCI lesion complexity was progressively and strongly associated with the 48-h risk of MACE, including MI, stent thrombosis, and ischaemia-driven revascularization (but not death). This relationship was independent of clinical syndrome acuity, ADP antagonist potency (use of 300 mg vs. 600 mg of clopidogrel or cangrelor), anticoagulation type and DES use, and numerous other baseline risk factors. In clopidogrel-treated patients the 48-h MACE rate ranged from 3.3% after PCI of lesions with no HRFs to 8.7% after PCI of lesions with ≥3 HRFs, a substantial short-term risk emphasizing the ongoing need for improved pharmacologic and device-based approaches to enhance the safety of complex PCI.

Compared with oral clopidogrel loading at the time of PCI, the potent, rapidly acting intravenous agent cangrelor (bolus plus 2-h to 4-h infusion) significantly reduced the 48-h rates of MACE, including MI, stent thrombosis and ischaemia-driven revascularization, independent of presentation with SIHD vs. ACS and the number of PCI lesion HRFs. No significant interaction was present between the relative treatment benefit of cangrelor in reducing these endpoints and the number of PCI lesion HRFs, in all patients and separately in those with SIHD and ACS. Thus, the absolute benefit of cangrelor will be greater as the baseline clinical and anatomic risk of PCI increases. Major adverse cardiac event rates in CHAMPION PHOENIX were higher after PCI in SIHD compared with ACS due to greater rates of peri-procedural MI in SIHD, a finding explainable by challenges in adjudicating PCI-induced myonecrosis in ACS patients in whom baseline biomarker levels are already elevated.[@ehy562-B15] However, stent thrombosis rates were greater in patients with ACS (as expected),[@ehy562-B16]^,^[@ehy562-B17] and steadily increased with the number of PCI target lesion HRFs. The absolute reduction in the 48-h rate of stent thrombosis following treatment with cangrelor compared with clopidogrel was particularly notable after PCI of lesions with ≥3 HRFs \[1.0% vs. 2.3%, OR (95% CI) 0.43 (0.23, 0.82)\], with 1.6% and 1.1% absolute stent thrombosis reductions in ACS and SIHD respectively. Thus, cangrelor may be of particular benefit during PCI of high-risk lesions in both patients with ACS and SIHD, compared with a clopidogrel loading dose at the time of the procedure. Withholding oral ADP receptor antagonist administration and administering intravenous cangrelor just prior to PCI to ensure complete inhibition of the platelet P2Y~12~ receptor in patients with unknown coronary anatomy is also consistent with the 2017 focused update on dual antiplatelet therapy from the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) Task Force.[@ehy562-B18] Finally, in the present study cangrelor did not increase major bleeding, the risk of which was independent of coronary lesion complexity.

Limitations
-----------

Although angiographic core laboratory analysis was pre-specified in the CHAMPION PHOENIX design, the present study was *post hoc*, and as such its results should be considered hypothesis-generating. Some high-risk lesion types were relatively infrequent; the study was not powered to examine the interaction between individual lesion types, treatments, and outcomes. The angiographic core laboratory definitions were pre-specified, and we did not study every type of high-risk lesion, PCI of some of which may not be affected by potent platelet inhibition (e.g. saphenous vein grafts).[@ehy562-B19] The proportion of PCI procedures performed by radial vs. femoral access and stent types used in practice may have changed since the performance of CHAMPION PHOENIX. However, by multivariable analysis the number of HRFs and use of clopidogrel rather than cangrelor were independent predictors of MACE after adjusting for these and other factors. The present study did not assess the relationship between the number of HRFs, ADP receptor inhibition, and the specific angiographic complications that may occur (e.g. side branch loss, no reflow, etc.). Such analyses are complicated by the fact that operators do not reliably film all complications. However, we have previously demonstrated that angiographic intraprocedural stent thrombosis is correlated with long and thrombotic lesions and clinical syndrome acuity (frequency greatest with STEMI, intermediate with NSTEACS and least with SIHD); is strongly correlated with subsequent death, MI, ischaemia-driven revascularization and out-of-cath lab stent thrombosis; and is reduced by cangrelor.[@ehy562-B13] The present study was performed before the SYNTAX score was in wide use; as such, the SYNTAX score was not determined. Finally, the CHAMPION PHOENIX trial compared cangrelor to a clopidogrel loading dose given at the time of PCI and excluded patients pre-loaded earlier or treated with ticagrelor or prasugrel. Such therapies would not likely have reduced the relationship between the number of HRFs and peri-procedural MACE, since this association was independent of cangrelor use. However, pre-loading with more potent ADP receptor antagonists may have attenuated the magnitude of the cangrelor effect observed.

Conclusions
===========

The number of high-risk target lesion features is strongly predictive of peri-procedural MACE in patients undergoing PCI, regardless of clinical syndrome acuity. Compared with a loading dose of clopidogrel in ADP receptor inhibitor-naïve patients, cangrelor reduced MACE occurring within 48 h after PCI, with a greater absolute effect as the number of treated HRFs increased in both SIHD and ACS. Major bleeding occurred infrequently regardless of lesion complexity and was not increased by cangrelor. The absolute benefit:risk profile for cangrelor will therefore be greatest during PCI in patients with complex coronary anatomy.
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[^1]: CABG, coronary artery bypass graft surgery; HRF, high-risk feature; NSTEACS, non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischaemic attack.

[^2]: *P*-value for trend for categorical data, F-test for continuous data.

[^3]: Denotes statistically significant differences between each pair (*P* \< 0.05 by χ^2^ test for categorical data, by F-test for continuous data).

[^4]: GUSTO, Global Use of Strategies to Open Occluded Coronary Arteries; HRF, high-risk feature; MACE, major adverse cardiac events; TIMI, Thrombolysis in Myocardial Infarction.

[^5]: ACS, acute coronary syndrome; HRF, high-risk feature; SIHD, stable ischaemic heart disease.
